Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 22 Dec 2018)

Commentary
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention…
Authors: Chester B. Good, Natasha Parekh and Inmaculada Hernandez
Citation: BMC Medicine 2018 16:238
Published on: 18 December 2018